Autophagy modulation: a prudent approach in cancer treatment? Eleanor BishopTracey D. Bradshaw Review Article Open access 04 September 2018 Pages: 913 - 922
Autophagy therapeutics: preclinical basis and initial clinical studies Lei ZhanJun LiBing Wei Review Article 17 September 2018 Pages: 923 - 934
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial) Joan MaurelSantiago Sánchez-CabúsLaureano Fernández-Cruz Original Article 17 September 2018 Pages: 935 - 943
Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma Arabinda DasFraser Henderson Jr.David Cachia Original Article 12 September 2018 Pages: 945 - 952
The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer Koki GotoRyusei MatsuyamaItaru Endo Original Article Open access 14 September 2018 Pages: 953 - 960
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer Robert J. MayerHoward S. HochsterAxel Grothey Original Article 22 October 2018 Pages: 961 - 969
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer Seiichi HayatoRobert ShumakerZiad Hussein Original Article Open access 22 September 2018 Pages: 971 - 978
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer Nicolas MartinNicolas IsambertJean-Pierre Delord Original Article Open access 22 October 2018 Pages: 979 - 986
Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer Helena TaflinElisabeth OdinYvonne Wettergren Original Article Open access 29 September 2018 Pages: 987 - 997
Lactobacillus supplementation prevents cisplatin-induced cardiotoxicity possibly by inflammation inhibition Lianbi ZhaoChangyang XingLijun Yuan Original Article 01 October 2018 Pages: 999 - 1008
Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway Lei YongYunlong MaXiaoguang Liu Original Article Open access 28 September 2018 Pages: 1009 - 1020
A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients Tetsuya HamaguchiAkihito TsujiTetsuji Tsukamoto Original Article Open access 04 October 2018 Pages: 1021 - 1029
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403 Naohiro OdaKastuyuki HottaKatsuyuki Kiura Original Article 01 October 2018 Pages: 1031 - 1038
Oncogenic roles of serine–threonine kinase receptor-associated protein (STRAP) in osteosarcoma Dumnoensun PruksakornJeerawan KlangjorhorChantragan Srisomsap Original Article 01 October 2018 Pages: 1039 - 1047
FOXC2 promotes epithelial–mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells Yuwen HeHui XieLi Wei Original Article 09 October 2018 Pages: 1049 - 1059
No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer Takeo KosakaHiroshi HongoMototsugu Oya Original Article Open access 03 October 2018 Pages: 1061 - 1066
Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer Tomas VilimasAmy Q. WangUdo Rudloff Original Article Open access 10 October 2018 Pages: 1067 - 1080
Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells Yong CaoYan LinChangqing Zheng Short Communication 28 August 2018 Pages: 1081 - 1086
Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239–1247 Michael EichbaumChristine Eichbaum Letter to the Editor 25 April 2018 Pages: 1087 - 1088